PROGRAM
Program
May 14, 2023 Sun. | |
AM | <Opening remarks> -Masayuki Amagai -Enno Schmidt “In memory of Detlef Zillikens” -Patrick Dunn (IPPF) |
| AM | <Invited Lectures 1: Cutting-edge bench-to-bed science> Chair: John Stanley, Soo-Chan Kim “Sensing inflammation in the skin and beyond” Brian Kim
“Translational research in vitiligo: Gaining insight into mechanisms of organ-specific autoimmunity” John Harris |
AM | Session 1 <Epithelial structure and signaling> Chair: Carien Niessen, Eliane Müller “Identification of a novel endoplasmic reticulum-desmosome complex: Potential roles in blistering skin diseases” Andrew Kowalczyk “Connecting desmoglein 1’s functions in epidermal development and disease” Kathleen Green “Signaling regulating keratinocyte adhesion in pemphigus” Jens Waschke |
AM | <Sponsored seminar (Takeda Pharmaceutical Co., Ltd.)> Chair: Takashi Hashimoto, Hideyuki Ujiie “Anti-idiotypic antibodies against autoantibodies in autoimmune blistering diseases” Hiroaki Iwata “Risk factors of bullous pemphigoid” Kaisa Tasanen |
PM | Session 2 <Immunological mechanisms of pemphigus> Chair: Animesh Sinha, Yumi Aoyama “Impact of CD4+ T cells on the pathomechanism of pemphigus” Jong Hoon Kim “Autoreactive B cell differentiation in ectopic lymphoid-like structures of pemphigus lesions” Meng Pan “Bead assays for pathogenic autoantibodies in pemphigus” Ken Ishii |
PM | Session 3 <Immunological mechanisms of pemphigoid> Chair: Zhi Liu, Luca Borradori “Th2 immune response in bullous pemphigoid” Hideyuki Ujiie
“Granzyme B in pemphigoid diseases” Sho Hiroyasu |
PM | Session 4 <Presentations selected from submitted abstracts> Chair: Daisuke Tsuruta, Kyle Amber “Conformational epitope mapping of autoantibodies against BP180 in dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid” Shoko Mai “CRISPR/Cas9 screening identified KLF5 as novel modulator of desmosomal adhesion in pemphigus” Volker Spindler “Laminin beta4: a protein of the cutaneous basal membrane zone and autoantigen of anti-p200 pemphigoid” Stephanie Goletz “Structure of a novel endoplasmic reticulum-desmosome complex” Navaneetha Krishnan Bharathan “Deciphering the immune mechanism of autoreactive B cells in Pemphigus” Baptiste Janela |
PM | <Invited Lecture 2: Cutting-edge clinical science > Chair: Luis Diaz “JAK inhibitor treatment of inflammatory skin disease” Brett King |
PM | Poster Discussion |
|
|
May 15, 2023 Mon. | |
AM | Session 5 <Novel therapeutic strategies with T cells in pemphigus and pemphigoid> Chair: Jong Hoon Kim, Rudiger Eming “Fate induction in CD8 chimeric antigen receptor T-cells through asymmetric cell division” Christoph Ellebrecht
“Advances in immune engineering for pemphigus and beyond” Aimee Payne “T cell signature in pemphigus and derived immunotherapy” Michael Hertl
“Antigen-specific iTreg therapy for pemphigus” Hayato Takahashi |
AM | <Special lecture> Chair: Masayuki Amagai “Regulatory T cells in autoimmune disease” Shimon Sakaguchi |
AM | <Sponsored seminar (Zenyaku Kogyo Co,. Ltd.)> Chair: Yasuo Kitajima, Koji Hashimoto “Rituximab in pemphigus” Pascal Joly <Special seminar> “Evidence for treatment with conventional and emerging therapies in bullous pemphigoid” Pascal Joly |
PM | Session 6 <Novel therapeutic strategies with B cells in pemphigus and pemphigoid> Chair: Luis Diaz, Barbara Horvath “BTK inhibitors in pemphigus treatment” Jun Yamagami
“FcRn inhibition as novel therapeutic option for autoantibody-mediated disorders” Enno Schmidt
“Complement activation as a driver of autoimmune bullous skin disease” Christoph Hammers
“Immunometabolism in pemphigoid diseases -Potential avenues for new therapeutic strategies” Christian Sadik
“Rituximab therapy for mucous membrane pemphigoid: A retrospective monocentric study with long-term follow-up in 109 patients” Philippe Musette |
PM | Future goals of therapeutic strategies for autoimmune skin diseases |
PM | Session 7 <Management of pemphigus and pemphigoid around the world> Chair: Luca Borradori, Victoria Werth “Are composite scores or IGA scores better for assessing treatment efficacy in pemphigus?” Dedee Murrell “Rituximab therapy for the treatment of pemphigus patients in Egypt -10 year experience” Marwah Adly Saleh “Management of pemphigus and pemphigoid in India” Vinay Keshavmurthy |
PM | <Closing remarks> -Masayuki Amagai |
Confirmed speakers
<Special Lecture>
 | Shimon Sakaguchi (Osaka, Japan) “Regulatory T cells in autoimmune disease” |
<Invited Lecture (in alphabetical order)>
 | John Harris (Massachusetts, USA) “Translational research in vitiligo: Gaining insight into mechanisms of organ-specific autoimmunity” |
 | Pascal Joly (Rouen, France) “Rituximab in pemphigus” “Evidence for treatment with conventional and emerging therapies in Bullous pemphigoid” |
 | Brian Kim (New York, USA) “Sensing Inflammation in the Skin and Beyond” |
 | Brett King (Connecticut, USA) “JAK inhibitor treatment of inflammatory skin disease” |
< Confirmed speakers in Sessions (in alphabetical order)>
 | Christoph Ellebrecht (Pennsylvania, USA) “Fate induction in CD8 chimeric antigen receptor T-cells through asymmetric cell division” |
 | Kathleen Green (Illinois, USA) “Connecting Desmoglein 1’s Functions in Epidermal Development and Disease” |
 | Christoph Hammers (Lübeck, Germany) “Complement activation as a driver of autoimmune bullous skin disease“ |
 | Michael Hertl (Marburg, Germany) "T cell signature in pemphigus and derived immunotherapy" |
 | Sho Hiroyasu (Osaka, Japan) "Granzyme B in pemphigoid diseases" |
 | Ken Ishii (Chiba, Japan) “Bead assays for pathogenic autoantibodies in pemphigus” |
 | Hiroaki Iwata (Gifu, Japan) |
 | Vinay Keshavamurthy (Chandigarh, India) "Management of pemphigus and pemphigoid in India" |
 | Jong Hoon Kim (Seoul, Korea) “Impact of CD4+ T cells on the pathomechanism of pemphigus” |
 | Andrew Kowalczyk (Pennsylvania, USA) “Identification of a Novel Endoplasmic Reticulum-Desmosome Complex: Potential Roles in Blistering Skin Diseases” |
 | Dedee Murrell (Sydney, Australia) "Are composite scores or IGA scores better for assessing treatment efficacy in pemphigus?" |
 | Philippe Musette (Bobigny, France) “Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study with Long-Term Follow-Up in 109 Patients” |
 | Meng Pan (Shanghai, China) “Autoreactive B cell differentiation in ectopic lymphoid-like structures of pemphigus lesions” |
 | Aimee Payne (Pennsylvania, USA) “Advances in immune engineering for pemphigus and beyond” |
 | Christian Sadik (Lübeck, Germany) “Immunometabolism in pemphigoid diseases – Potential avenues for new therapeutic strategies” |
 | Marwah Adly Saleh (Cairo, Egypt) “Rituximab therapy for the treatment of pemphigus patients in Egypt- 10 years experience” |
 | Enno Schmidt (Lübeck, Germany) “FcRn inhibition as novel therapeutic option for autoantibody-mediated disorders” |
 | Hayato Takahashi (Tokyo, Japan) “Antigen-specific iTreg therapy for pemphigus” |
 | Kaisa Tasanen (Oulu, Finland) “Risk factors of bullous pemphigoid” |
 | Hideyuki Ujiie (Hokkaido, Japan) “Th2 immune response in bullous pemphigoid” |
 | Jens Waschke (Munich, Germany) “Signaling regulating keratinocyte adhesion in pemphigus” |
 | Jun Yamagami (Tokyo, Japan) “BTK inhibitors in pemphigus treatment” |